Bryn partners with Aptra for nasal epinephrine treatment
Bryn Pharma has entered into an agreement with Aptar, a leading drug delivery systems provider, for the supply and worldwide exclusive right to use Aptar’s novel, FDA approved Bidose, or BDS nasal device for the delivery of epinephrine to treat anaphylaxis.
The company said that up to 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms. Current practice parameters recommend that physicians prescribe two epinephrine auto-injectors to be carried by their patients at all times.
This month, Bryn completed dosing in its pivotal clinical trial of its Epinephrine Nasal Spray (BRYN-NDS1C), using a single, portable, optimized Aptar BDS device capable of delivering two therapeutic doses of epinephrine, replacing the need to carry two epinephrine auto-injectors.
“Studies have shown that the majority of people at risk for anaphylaxis do not carry two epinephrine auto-injectors with them at all times, putting them at greater risk of severe complications during an allergic reaction,” said David Dworaczyk, Bryn Pharma CEO. We are excited to partner with Aptar Pharma to develop a product that can provide patients with a life-saving treatment that fits in a pocket, is easy to use and complies with practice parameters."